Summary & Overview
HCPCS C9032: Voretigene Neparvovec-Rzyl Injection, 1 Billion Vector Genome
HCPCS Level II code C9032 designates the gene therapy product voretigene neparvovec-rzyl, billed per unit of 1 billion vector genome for injection. This code is important nationally because it captures administration and acquisition of a high-cost, one-time ocular gene therapy used for inherited retinal diseases. Accurate use of C9032 affects billing consistency, payer coverage determinations, and budgeting for specialty therapies in ambulatory surgical and hospital outpatient settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for voretigene neparvovec-rzyl, typical sites of service, and the billing implications tied to a per-vector-genome unit definition. The publication summarizes benchmarks for utilization and reimbursement approaches, highlights relevant policy updates affecting coverage and coding, and outlines operational considerations for facilities that administer ocular gene therapies. It also flags areas where payer policies commonly vary—such as prior authorization requirements and documentation standards—to help billing and clinical teams align coding and submission practices with payer expectations.
Billing Code Overview
HCPCS Level II code C9032 represents the medication voretigene neparvovec-rzyl delivered as an injection, with the unit defined as 1 billion vector genome. This code describes a gene therapy product typically administered via an ocular route for delivery to the retina.
Service type: Gene therapy injection
Typical site of service: Ambulatory surgical center or hospital outpatient department (intraocular procedure)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A child or young adult with confirmed biallelic RPE65 mutation-associated retinal dystrophy presents to a specialized ophthalmology/retina clinic for consideration of gene replacement therapy with C9032 (voretigene neparvovec-rzyl). Typical presentation includes progressive nyctalopia (night blindness), visual field constriction, and reduced visual acuity documented on standardized testing. Pre-procedure evaluation includes genetic confirmation of biallelic RPE65 pathogenic variants, baseline best-corrected visual acuity, full-field stimulus testing (FST) or fundus autofluorescence, optical coherence tomography (OCT), visual field testing where feasible, and counseling regarding risks and benefits.
The clinical workflow: first, multidisciplinary assessment and informed consent are completed. Anesthesia evaluation is performed because the subretinal injection is typically done under general anesthesia in pediatric patients or sedation in adults. On the day of procedure, the patient undergoes sterile preparation; a vitreoretinal surgeon performs a pars plana vitrectomy followed by subretinal injection of C9032 delivering 1 billion vector genomes into the subretinal space, often in two blebs to cover the macular/central retina. Postoperative care includes topical and/or systemic corticosteroid regimen per protocol, close ophthalmic monitoring for inflammation, increased intraocular pressure, retinal detachment, or other complications, and functional follow-up at specified intervals to assess visual function improvements using FST and visual acuity testing.
Typical site of service: an ambulatory surgical center or hospital operating room specializing in ophthalmic vitreoretinal surgery.
Typical patient scenario: a 6–25-year-old patient with genetically confirmed RPE65-mediated inherited retinal dystrophy, baseline reduced visual function, and counseling indicating potential benefit from one-time subretinal administration of C9032 by a vitreoretinal surgeon under general anesthesia.